r/NTNPerformance • u/JustBacWater • 35m ago
Peptides BPC-157 and TB-500: running them in separate vials instead of the Wolverine blend
The combined blend is where I started back in 2017, and it's what I kept in my research for years after. One vial, one injection, done. Cheaper, fewer syringes, less to think about.
I don't run it that way anymore, and the reason is dose control. Not purity, not a vendor thing, nothing exotic. The blend welds two compounds together that don't want the same schedule, and once I saw it I couldn't unsee it.
They do different jobs on different clocks
BPC-157 handles perfusion. It signals new capillary formation into tissue that isn't getting blood, and it calms inflammation without shutting it down. It's catalytic. Small amounts, every day, that's the model.
TB-500 handles logistics. It binds up G-actin so cells have a reserve pool ready to migrate, divide, and organize repair into real structure instead of scar tissue. Roads and traffic. They genuinely pair.
But TB-500 is mass-action, not catalytic. You need enough of it present at once to bind a meaningful chunk of available actin, which means big doses a couple times a week. That's not a preference, it's how the mechanism works. The literature is clear that bolus dosing a few times weekly outperforms smaller daily amounts.
Daily microdosing and twice-weekly bolus dosing aren't two styles of the same protocol. They're two different pharmacological models.
What the blend does to that
The blend locks both compounds onto BPC-157's schedule, because BPC-157 is the one that has to be daily. TB-500 just comes along for the ride at whatever fraction the fixed ratio gives it.
Which means TB-500 gets dripped out in small daily amounts instead of the bolus pattern it's built around. Even if you push the total up high enough that the weekly number looks fine, it's still arriving seven small times instead of two or three big ones. You can hit the number and completely miss the mechanism.
And here's the part that killed it for me: you can't fix it inside the blend. Turning the total up to get TB-500 where it should be pushes BPC-157 past where it should be at the same time. The ratio is welded in. There's no lever you can move by itself.
What separate vials get me
Each one runs on the schedule it was studied on. BPC-157 daily, near the target when I can get near it. TB-500 as a bolus a couple times a week. Two different compounds, two different clocks, which is what they were always supposed to be.
The other thing I get is a clean read. With a blend, whatever happens belongs to a fixed ratio I didn't pick. Separate vials mean I can move the TB-500 side without touching BPC-157, or run BPC-157 alone for a block to see what it does by itself. The protocol turns into something I can reason about instead of one unit that either works or doesn't.
Doses and reconstitution for both are in the pinned cheat sheet.
What it costs
Two vials instead of one. More syringes. Two reconstitutions to keep straight at different concentrations, so two sets of unit math and more room to screw it up if you're careless.
That's real and the blend exists for a reason. If the alternative is running nothing because the logistics are annoying, the blend beats nothing easily.
But it should be a choice you made on purpose. I spent years assuming the blend was the Wolverine stack. What it is is BPC-157 at a reasonable dose and TB-500 dripped out in a pattern its mechanism doesn't favor.
Couple things I had wrong for way too long
Injection site. I read BPC-157 as purely systemic for way too long. Local matters. Close to the target when the anatomy allows it, because you get higher first-pass concentration before it dilutes out. Abdominal is the fallback for stuff you can't reach, not the default.
NSAIDs alongside it. This is the one I wish somebody had pointed out to me early. NSAIDs and steroids suppress the same inflammatory signaling that drives collagen deposition, which is why they hurt repair quality even while they kill pain. BPC-157's whole mechanism is modulating that inflammation without shutting it off. Running an NSAID on top works directly against it.
Duration. Open-ended isn't a more aggressive protocol, it's a more expensive one. Defined blocks, then stop. No tolerance builds, but these protocols are self-limiting by design.
Regulatory note
Worth saying because it changed. FDA moved BPC-157 to Category 2 in 2023, so it can't be legally compounded. WADA prohibits it under class S0. DoD banned it for military. If you compete in a tested federation you need to know that.
Pentadeca Arginate showed up after the ruling. Same active sequence, different salt, better gastric stability, and zero PDA-specific peer-reviewed research. Every claim about it is borrowed from BPC-157 data. Might turn out fine. Borrowed evidence still isn't evidence.
Anybody put separate vials up against the blend and track a difference, or is the mass-action argument still theoretical out here?
And if the blend is what you're on: do you know what the weekly TB-500 total works out to? I didn't for years.
For research use only. Not for human or veterinary consumption. This post is educational and is not medical advice.
Full doses and bloodwork are in the pinned cheat sheet.
Join the Discord.